*March 2025*
What is the next step for patients with EGFR-mutated non-small cell lung cancer (NSCLC) whose disease has progressed on first-line osimertinib (Tagrisso), but who have no identifiable biomarkers to guide second-line therapy?
Early results from the phase 2 ORCHARD platform study suggest that the next step could be adding the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd; Datroway) to osimertinib. Initial efficacy results indicate that the combination can evoke objective responses in slightly more than one-third of such patients and extend progression-free survival (PFS) by nearly a year. The findings were presented in an oral abstract session on March 26 at the 2025 European Lung Cancer Conference (ELCC), held in Paris, France. Read more.
